Evidence map›Paper›PMID 31667686›Full record

ArticleClinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico2020

MiR-130b/TNF-α/NF-κB/VEGFA loop inhibits prostate cancer angiogenesis.

H Q Mu, Y H He, S B Wang, S Yang, Y J Wang, C J Nan, Y F Bao, Q P Xie, Y H Chen

Abstract read
PubMed Publisher
In one paragraph

Article in Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 54 papers.

0numbers the graph read from it
0cells of the map it votes in
54citing papers in PubMed
4.4field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

54 citing papers in PubMed, 91 citations in OpenAlex.

  1. Review
  2. LncRNA FEZF1-AS1 promotes the tumorigenesis and suppresses ferroptosis in non-small cell lung cancer through the TNF-α/NF-κB pathway.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2026
    Article
  3. Review
  4. Review
  5. Article
  6. Review
  7. Article
  8. Review
  9. Review
  10. Review
  11. Review
  12. Review
  13. Article
  14. Article
  15. Review
  16. Review
  17. Review
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 1 institution in 1 country.

H Q MuDepartment of Urology, The Second Affiliated Hospital of Wenzhou Medical University, Wenzhou, Zhejiang, China.
Y H HeDepartment of Urology, The Second Affiliated Hospital of Wenzhou Medical University, Wenzhou, Zhejiang, China.
S B WangDepartment of Urology, The Second Affiliated Hospital of Wenzhou Medical University, Wenzhou, Zhejiang, China.
S YangDepartment of Urology, The Second Affiliated Hospital of Wenzhou Medical University, Wenzhou, Zhejiang, China.
Y J WangDepartment of Urology, The Second Affiliated Hospital of Wenzhou Medical University, Wenzhou, Zhejiang, China.
C J NanDepartment of Urology, The Second Affiliated Hospital of Wenzhou Medical University, Wenzhou, Zhejiang, China.
Y F BaoDepartment of Urology, The Second Affiliated Hospital of Wenzhou Medical University, Wenzhou, Zhejiang, China.
Q P XieClinical Laboratory, The Second Affiliated Hospital of Wenzhou Medical University, Wenzhou, Zhejiang, China.
Y H ChenDepartment of Urology, The Second Affiliated Hospital of Wenzhou Medical University, Wenzhou, Zhejiang, China. muhaiqi2015@126.com.ORCID http://orcid.org/0000-0002-6112-5689
Wenzhou Medical University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundAngiogenesis is a critical biological process essential for solid cancer growth and metastasis. It has been shown that microRNAs (miRNAs) play a vital role in a variety of biological processes in cancers. However, whether miR-130b is involved in prostate cancer angiogenesis remains ill-defined.

methodsWe performed the miRNA microarray to analyze miRNA expression in human prostate cancer specimens. In vitro gain-of-function assays and loss-of-function assays were conducted to explore the potential functions of miR-130b in human prostate cancer cells. Correlation analysis and dual-luciferase reporter assay were performed to validate whether tumor necrosis factor-α (TNF-α) was a direct target of miR-130b. The Matrigel plug and tumor vascular imaging assays were performed to confirm the anti-angiogenic activity of miR-130b in nude mice.

resultsWe found that miR-130b was one of the miRNAs being most significantly downregulated. Subsequently, we found that miR-130b expression was markedly downregulated in human prostate cancer cell lines. Down-regulation of miR-130b in prostate cancer cells significantly promoted the proliferation, invasion and tubule formation of human umbilical vein endothelial cells (HUVECs), while ectopic expression of miR-130b blocked prostate cancer angiogenesis in vitro and in vivo. Mechanistic analyses indicated that tumor necrosis factor-α (TNF-α) was regulated by miR-130b directly. MiR-130b attenuated nuclear factor-κB (NF-κB) signaling and its downstream gene vascular endothelial growth factor-A (VEGFA) by directly inhibiting TNF-α expression. Additionally, subsequent investigations identified that the ectopic level of VEGFA markedly abrogated the anti-angiogenic effect induced by miR-130b. Interestingly, VEGFA could in turn decrease the expression of miR-130b, thus forming a negative feedback loop that drives the angiogenesis of prostate cancer.

conclusionThese findings show that miR-130b/TNF-α/NF-κB/VEGFA feedback loop is significantly correlated with angiogenesis in prostate cancer and miR-130b could be regarded as potential therapeutic target for prostate cancer anti-angiogenesis treatment.

Indexed as

Gene Expression Regulation, NeoplasticAnimalsApoptosisBiomarkers, TumorCell ProliferationHumansMaleMiceMice, Inbred BALB CMice, NudeMicroRNAsNeovascularization, PathologicNF-kappa BPrognosisProstatic NeoplasmsSignal TransductionBiomarkers, TumorMicroRNAsMIRN130 microRNA, humanNF-kappa BTumor Necrosis Factor-alphaVascular Endothelial Growth Factor AVEGFA protein, humanAngiogenesismiR-130bProstate cancerTNF-α

Identifiers

PMID31667686
OpenAlexW2982294046

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.